Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831730 | 0.89 | HPGD (0.52) | HPGDHDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL14254961 | 0.83 | HDAC3 (0.52) | HPGDHDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL8360681 | 0.82 | HDAC2 (0.68) | HDAC8HDAC3HDAC2HDAC6HDAC1 | |
| SCHEMBL14254962 | 0.82 | HDAC2 (0.68) | HDAC8HDAC3HDAC2HDAC6HDAC1 | |
| SCHEMBL4831736 | 0.81 | HDAC3 (0.56) | HPGDHDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL2895497 | 0.78 | HDAC1 (0.54) | HDAC8HDAC3HDAC2HDAC6HDAC1 | |
| SCHEMBL18256357 | 0.77 | ENPP2 (0.65) | HDAC8HDAC3HDAC2HDAC6HDAC1 | |
| SCHEMBL18256306 | 0.77 | PTPRC (0.53) | HDAC8HDAC3HDAC2HDAC6HDAC1 | |
| SCHEMBL18256337 | 0.77 | ENPP2 (0.65) | HDAC8HDAC3HDAC2HDAC6HDAC1 | |
| SCHEMBL18256356 | 0.75 | ENPP2 (0.54) | HDAC8HDAC3HDAC2HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1231919-B1 | Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors | SLOAN KETTERING INST CANCER (US) | 2015-09-30 | — | — | EP | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-26 | — | — | US | disclosed |
| US-7126001-B2 | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1231919-A4 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-01 | — | — | US | disclosed |
| US-6511990-B1 | Selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-01-28 | — | — | US | disclosed |
| EP-1231919-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001018171-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HPGD 377/4885HDAC8 17/4885HDAC3 2/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HPGD 377/4885HDAC8 17/4885HDAC3 2/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HPGD 377/4885HDAC8 17/4885HDAC3 2/4885 |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HPGD 488/4885HDAC8 18/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.